Eli Lilly and Company

Other

Pfizer Corporation

Stephanie Ann Sweetana

Arvind L Thakkar

Kenneth Philip Moder

Kerry John Hartauer

Nathaniel Milton

James Lawrence Sabatowski

Lowell L Gibson

Julian L Stowers

George J Cullinan

Henry U Bryant

James Allen Monn

Anne H Dantzig

Maria Angeles Martinez-Grau

Concepcion Pedregal-Tercero

Ana Belen Bueno Melendo

George M Grass

Alfonso De Dios

Luisa Maria Martin-Cabrejas

Jose Alfredo Martin

Carlos Montero Salgado

Carmen Dominguez-Fernandez

Marc Francis Herin

David E Magee

Paul C Francis

Nathanial Milton

Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.

Echinocandin pharmaceutical formulations containing micelle-forming surfactants

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

Prodrugs of excitatory amino acids

This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Solid orally administerable raloxifene hydrochloride pharmaceutical

This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.

The present invention provides aqueous inclusion complexes of certain known benzothiophene compounds, particularly Raloxifene, and water soluble cyclodextrins. Also provided are pharmaceutical compositions of such inclusion complexes, and methods of using these complexes for inhibiting bone loss and reducing serum cholesterol in mammals.

Aqueous solution inclusion complexes of benzothiophene compounds with

An apparatus for determining transport characteristics across membranes and tissue sections comprises a plurality of cell blocks, where each cell block includes a pair of half-cells which hold the membrane or tissure section therebetween. A circulation path is provided in each half-cell block for exposing a fluid to one side of the membrane or tissue section. The cell blocks are maintained linearly within a base unit including a front plate and a back plate. The front and back plates are heated to maintain the cell blocks at a desired temperature.

Apparatus for in vitro determination of substances across membranes,

Growing community of inventors

Bloomington, IN, United States of America

Stephanie Ann Sweetana